Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois. .
Cancer (Impact Factor: 4.9). 01/2013; 119(2). DOI: 10.1002/cncr.27730
Source: PubMed

ABSTRACT BACKGROUND: Lung adenocarcinomas can be distinguished by identifying mutated driver oncogenes, including epidermal growth factor receptor (EGFR) and KRAS. Mutations in EGFR are associated with both improved survival as well as response to treatment with erlotinib and gefitinib. However, the prognostic significance of KRAS has not been evaluated in large numbers of patients and remains controversial. For the current report, the authors examined the association of EGFR and KRAS mutations with survival among patients with advanced lung adenocarcinomas. METHODS: Data were analyzed from patients with advanced lung adenocarcinomas who had known EGFR and KRAS mutation status evaluated between 2002 and 2009. The collected clinical variables included age, sex, Karnofsky performance status, smoking history, and treatment history. Overall survival from the diagnosis of advanced disease was analyzed using Kaplan-Meier and Cox proportional hazard methods. RESULTS: In total, 1036 patients were evaluated, including 610 women (59%) and 344 never-smokers (33%). The median patient age was 65 years (range, 25-92 years), and the majority of patients (81%) had a Karnofsky performance status ≥80%. In multivariate analysis, EGFR mutations were associated with longer overall survival (hazard ratio, 0.6; P < .001), and KRAS mutations were associated with shorter survival (hazard ratio, 1.21; P = .048). CONCLUSIONS: KRAS mutations predicted shorter survival for patients with advanced lung adenocarcinomas. The presence of EGFR and KRAS mutations define distinct subsets of patients with lung adenocarcinomas and should be determined in patients when they are diagnosed with advanced disease. Clinical trial reports should include EGFR and KRAS mutation status along with other prognostic factors. Cancer 2012. © 2012 American Cancer Society.

  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND:: We hypothesize that among patients with lung cancers the KRAS/EGFR mutation profile and overall survival of collegiate smokers (former smokers who smoked between 101 lifetime cigarettes and 5 pack-years) are distinct from those of never smokers and former smokers with 15 pack-years or more. METHODS:: We collected age, sex, stage, survival, and smoking history for patients evaluated from 2004 to 2009 with advanced stage lung cancers and known KRAS/EGFR status. Mutation profile and overall survival were compared using Fisher's exact test and log-rank test, respectively. RESULTS:: Data were available for 852 patients with advanced-stage lung cancers with known KRAS/EGFR status, of which 6% were collegiate smokers, 36% were never smokers, and 30% were former smokers with 15 pack-years or more. The mutation profile of collegiate smokers (15% KRAS mutations, 27% EGFR mutations) was distinct from those of never smokers (p < 0.001) and former smokers with 15 pack-years or more (p < 0.001) and not significantly different from those of former smokers with 5 to 15 pack-years (p = 0.9). Median overall survival for collegiate smokers was 25 months, compared with 32 months for never smokers (p = 0.4), 33 months for former smokers with 5 to 15 pack-years (p = 0.48), and 21 months for former smokers with 15 pack-years or more (p = 0.63). CONCLUSIONS:: Collegiate smokers with advanced-stage lung cancers represent a distinct subgroup of patients with a higher frequency of KRAS mutations and lower frequency of EGFR mutations compared with never smokers. These observations reinforce the recommendation for routine mutation testing for all patients with lung cancers and that no degree of tobacco exposure is safe.
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 01/2013; 8(1):123-125. DOI:10.1097/JTO.0b013e31827914ea · 5.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION:: Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. METHODS:: NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board. Cancers with exon 20 insertions were indentified, sequences were characterized, and effectiveness of different treatment regimens was reviewed retrospectively. Clinical characteristics and survival were compared with cancers harboring common EGFR mutations and cancers with wild-type EGFR. RESULTS:: One thousand eighty-six patients underwent EGFR genotyping from 2004 to 2012. Twenty seven (2.5%) harbored exon 20 insertions, making up 9.2% of all cancers with documented EGFR mutations. Compared with wild-type cancers, those with exon 20 insertions were more commonly found in never-smokers and Asian patients. Insertion sequences were highly variable, with the most common variant (V769_D770insASV) making up only 22% of cases. Median survival of patients with exon 20 insertions was 16 months, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations. CONCLUSIONS:: Patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but a poorer prognosis. The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.
    Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 02/2013; 8(2):179-184. DOI:10.1097/JTO.0b013e3182779d18 · 5.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thymic neoplasms constitute a broad category of rare lesions with a wide spectrum of pathologic characteristics and clinical presentations which therefore require a high index of suspicion to diagnose. The natural history of the disease is seldom predictable, anywhere from an indolent to an aggressively malignant course. Although the classification and staging of these lesions are complex and controversial, complete radical surgical resection remains the gold standard of therapy. Radiation and chemotherapy are important elements of the multimodality approach to treating these patients and it is important for thoracic surgeons to work closely with their colleagues in other disciplines in the management of and future research endeavors in thymic neoplasm. In this review, we discuss the evaluation of the patient with an anterior mediastinal mass, the classification and staging of thymic neoplasms, the role of surgery, radiation and chemotherapy in treating this disease, as well as future directions in research for novel targeted therapies.
    04/2013; 5(2):173-83. DOI:10.3978/j.issn.2072-1439.2013.01.12